Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Guideline on HCT for Certain Lymphoma Types

Biol Blood Marrow Transplant; ePub 2017 Aug 7; Kharfan-Dabaja, et al

The American Society for Blood and Marrow Transplantation has published clinical practice recommendations related to the role of hematopoietic cell transplantation (HCT) for specific histologic subtypes of mature T-cell and NK/T-cell lymphomas.

Specifically, auto-HCT is recommended for:

  • Front-line consolidation in PTCL-NOS, AITL, ALCL-ALK negative, NK/T-cell (disseminated), EATL, and hepatosplenic lymphomas.
  • NK/T-cell (localized and disseminated), EATL, subcutaneous panniculitis-like T-cell, and ALCL-ALK positive lymphomas in relapsed-sensitive disease.
  • PTCL-NOS, AITL, and ALCL-ALK negative if it was not performed in front-line.

Auto-HCT is not recommended for any of these histologic subtypes in primary or relapsed refractory stage. Meanwhile, allo-HCT is recommended for:

  • Front-line consolidation in NK/T-cell (disseminated), ATLL (acute and lymphoma-type), and hepatosplenic lymphomas.
  • For PTCL-NOS, AITL, ALCL-ALK negative, ALCL-ALK positive, NK/T-cell (localized and disseminated), ATLL (acute, lymphoma type, smoldering/chronic), MF/SS (advanced stage IIB-IVB or tumor stage/extracutaneous), EATL, subcutaneous panniculitis-like T-cell, and hepatosplenic lymphoma in relapsed-sensitive stage.
  • For any aforementioned histologic subtypes in primary or relapsed refractory stage.

Citation:

Kharfan-Dabaja M, Kumar A, Ayala E, et al. Clinical practice recommendations on indication and timing of hematopoietic cell transplantation in mature t-cell and NK/t-cell lymphomas: An international collaborative effort on behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation. [Published online ahead of print August 7, 2017]. Biol Blood Marrow Transplant. doi:10.1016/j.bbmt.2017.07.027.